This conference will focus on the differences between the present and new requirements for managing clinical trials in the face of forthcoming changes, including the new EU clinical trials Regulation but also conducting novel complex innovative design trials. Regulators and other decision-makers, together with various experts in the field, will debate how the new legislation will impact the processes for the design, submission, and approval, and managing European clinical trials in the future.
TransCelerate’s session is on “Future Developments and Projects on Clinical Trial Regulations” featuring Alison Bond (Amgen) as a speaker.